Celldex Therapeutics reported a net loss of $53.8 million for the first quarter of 2025, an increase from $32.8 million in the same period last year. Total revenues significantly increased to $695 thousand, driven by a rise in contracts and grants. Operating expenses also saw a substantial increase, primarily due to higher research and development costs related to the expanded development of barzolvolimab.

Celldex Therapeutics reported a decrease in total revenues for Q4 2024 compared to Q4 2023, primarily due to a decrease in services performed under manufacturing and research and development agreements. The company experienced an increase in R&D and G&A expenses, leading to a higher net loss for the quarter.

Celldex reported a net loss of $42.1 million, or ($0.64) per share, for the third quarter of 2024. Total revenue was $3.2 million, and research and development expenses were $45.3 million. Cash, cash equivalents, and marketable securities totaled $756.0 million as of September 30, 2024.

Celldex reported a net loss of $35.8 million, or ($0.54) per share, for the second quarter of 2024. The company's cash, cash equivalents and marketable securities totaled $802.3 million as of June 30, 2024, which is expected to fund operations through 2027. Total revenue was $2.5 million in the second quarter of 2024.

Celldex Therapeutics reported its Q1 2024 financial results, with a revenue of $0.2 million and a net loss of $32.8 million. The company's cash position is strong at $823.8 million, expected to fund operations through 2027.

Celldex Therapeutics reported Q4 2023 financial results, with a total revenue of $4.1 million and a net loss of $43.3 million, or ($0.83) per share. Cash, cash equivalents, and marketable securities as of December 31, 2023, were $423.6 million. The company believes its current financial resources are sufficient to fund planned operations into 2026.

Celldex Therapeutics reported its Q3 2023 financial results, with total revenue of $1.5 million and a net loss of $38.3 million, or ($0.81) per share. The company's cash, cash equivalents, and marketable securities totaled $235.3 million as of September 30, 2023, expected to fund operations through 2025.

Celldex Therapeutics reported its Q2 2023 financial results, with total revenue of $0.3 million and a net loss of $30.5 million, or ($0.65) per share. The company's cash, cash equivalents, and marketable securities totaled $252.7 million as of June 30, 2023, expected to fund operations through 2025.

Celldex reported a total revenue of $1.0 million for the first quarter of 2023, primarily driven by an increase in services performed under the agreement with Rockefeller University. The net loss for the quarter was $29.4 million, or ($0.62) per share. Cash, cash equivalents, and marketable securities totaled $278.4 million as of March 31, 2023.

Celldex reported a net loss of $26.5 million, or ($0.56) per share, for the fourth quarter of 2022. Total revenue was $1.6 million, and research and development expenses were $22.9 million. Cash, cash equivalents, and marketable securities totaled $305.0 million as of December 31, 2022.

Celldex reported its Q3 2022 financial results, highlighting progress across multiple programs, including the initiation of Phase 2 studies for barzolvolimab in chronic urticaria. The company anticipates data readouts from the barzolvolimab program starting in December and is advancing its bispecific antibody platform with CDX-585 expected to enter the clinic in 2023. Celldex believes its cash is sufficient to fund operations through 2025.

Celldex reported a net loss of $36.0 million, or ($0.77) per share, for the second quarter of 2022. Total revenue was $0.2 million, and cash, cash equivalents, and marketable securities totaled $356.8 million as of June 30, 2022.

Celldex Therapeutics reported a net loss of $23.1 million, or ($0.49) per share, for the first quarter of 2022. Cash, cash equivalents and marketable securities as of March 31, 2022 were $380.5 million. The company believes that the cash, cash equivalents and marketable securities at March 31, 2022 are sufficient to meet estimated working capital requirements and fund planned operations through 2025.

Celldex Therapeutics reported fourth-quarter financial results, with total revenue of $0.3 million and a net loss of $20.1 million, or ($0.43) per share. The company's cash, cash equivalents, and marketable securities totaled $408.3 million as of December 31, 2021, and they anticipate sufficient funds to support operations through 2025.

Celldex Therapeutics reported a net loss of $20.5 million, or ($0.45) per share, for the third quarter of 2021. The company's cash, cash equivalents and marketable securities were $423.1 million as of September 30, 2021, which they believe is sufficient to fund planned operations through 2025.

Celldex reported a total revenue of $3.5 million and a net loss of $13.4 million, or ($0.34) per share, for the second quarter of 2021. The company's cash, cash equivalents and marketable securities were $164.0 million as of June 30, 2021. They raised $287 million in gross proceeds from a follow-on public offering of common stock, closed in July 2021.

Celldex Therapeutics reported their Q1 2021 financial results. They had a total revenue of $0.7 million and a net loss of $16.5 million, or ($0.42) per share. Cash, cash equivalents and marketable securities were $176.1 million as of March 31, 2021.

Celldex Therapeutics reported a net loss of $21.9 million for the fourth quarter of 2020, with total revenue of $3.8 million. The company's cash, cash equivalents, and marketable securities totaled $194.4 million as of December 31, 2020, which they believe is sufficient to fund planned operations through 2023. They also had significant progress across their pipeline, especially with CDX-0159.

Celldex Therapeutics reported $0.7 million in revenue for the third quarter of 2020. The company's cash position remains strong with $199.6 million in cash, cash equivalents, and marketable securities. Celldex believes its current cash reserves are sufficient to fund operations through 2023.

Celldex reported a net loss of $11.0 million, or ($0.50) per share, for the second quarter of 2020. The company's cash, cash equivalents, and marketable securities totaled $206.9 million as of June 30, 2020, which they believe is sufficient to fund operations through 2023. They are discontinuing development of CDX-3379.

Celldex Therapeutics reported its Q1 2020 results, highlighting progress in advancing their pipeline despite challenges from the COVID-19 pandemic. Key developments include completing enrollment in the Phase 1 study of CDX-0159 and preparing to advance CDX-527 into a Phase 1 study. The company's cash position remains strong enough to fund operations into the second quarter of 2021.

Celldex Therapeutics reported a net loss for Q4 2019, but is making progress with its CDX-1140, CDX-3379, and CDX-0159 programs. The company believes its cash position is sufficient to fund operations into the first quarter of 2021.